XLV Health Care Select Sector SPDR Fund

$XLV continues its rally toward 184.10 or higher, maintaining its bullish sequence from the November 9, 2026 low after reacting higher from the Blue Box area. Last month, we anticipated a zigzag correction into the 167.09–162.48 Blue Box, where price found support at 165.11 and reversed higher, offering buyers a profitable long opportunity. Another move anticipated, another opportunity captured. Were you able to catch this rally? #XLV #ElliottWave #BlueBox #Trading

$XLV Health Care Sector ETF pushes higher... could confirm breakout with follow on buying. #IBDPartner

$XLV — Correction Approaching a High-Probability Buying Zone XLV was unfolding an A-B-C correction from the recent peak, with wave C expected to extend into the 167.09–162.48 Blue Box. 📌 What we expected: the larger structure remained on the Right Side higher, so we anticipated buyers to appear once price reached this extreme area. 👀 The plan was to wait for the correction to complete inside the Blue Box rather than chase the decline. #XLV #Healthcare #BlueBox #ElliottWave #Trading

$XLV Quick 178.67 to 179.98 flip, strength has been here, in $MAGS $XLE … semis/photonics names offering occasional bounces but cannot really get interested in longs until we see a $SOXX 200 day

$XLV (Weekly & 195-Min Renko) System Status: GO (2nd Green Brick Confirmed) Setup Trigger (195-Min 1% Renko) • 2nd Green Brick Confirmed: Printed at $170.00 off 20-EMA/PSAR support ($165.49–$166.16) • StochRSI: Rebounding out of oversold zone (0.306) • Extension: Low at 2.31% above 20-EMA ($166.16) Higher-Timeframe Support (Weekly) • Weekly RSI(14): 61.68 (Healthy trend expansion) • Weekly Renko: Rebounded off $165.87 to print Green Brick ($169.29) above 20-EMA ($162.72) The Takeaway: System buy signal is LIVE with 2nd green brick confirmed at $170.00. Risk is clearly defined below PSAR ($165.49) & 20-EMA ($166.16). Execution Checklist • Entry: Buy zone ~$170.00 • Hard Stop Loss: $165.40 • Invalidation: Close if 195-min red brick prints below $165.49 $SPY $QQQ

Summary of $XLV and Industries Broad strength: Every health care group is above a rising 20 EMA, with ADX rising and +DI well above -DI. Pharmaceuticals: The biggest mover. It gapped up and closed at a new high for the move after weeks of base building. Medical Supplies and Medical Equipment: Steady, orderly climbs well above their 20 EMAs, the cleanest trend structure of the group. Health Care Providers: Sharp recovery from its lows, now back above its 20 EMA. Biotechnology: Strong, but it is news-driven and excluded from your scan. Takeaway: Health care leadership is broad, with Pharmaceuticals, Medical Supplies, and Medical Equipment the best fits for the system. Health Care Providers is also strong but excluded in your scan, so those names won’t appear. Check the XLV 195-min Renko for the Step 3 test before any entry, and cap healthcare at 2 positions. $SPY $QQQ $DIA

$XLV — Correction Approaching a Key Extreme Area XLV was unfolding an A-B-C correction after completing the previous bullish cycle. 📌 What we expected: another leg lower in wave (c) toward the 167.09–162.48 extreme area, where buyers could begin to appear. 👀 The larger structure remained on the Right Side higher, so the focus was on waiting for the correction to reach this high-frequency zone. #XLV #Healthcare #ElliottWave #BlueBox #Trading

$XLV & Health Care Sub-Industry Breakdown Health Care Sector (XLV): $177.19 (+1.86%), surging out of consolidation above rising moving averages. Medical Equipment ($DJUSAM): $2522.25 (+2.43%), breaking out above prior resistance with strong bullish acceleration. ⭐ Biotechnology ($DJUSBT) [Best]: $3898.31 (+1.75%), persistent high-tight trend breaking to new highs above $3819.21. ⭐ Health Care Providers ($DJUSHP) [Best]: $3150.96 (+2.09%), explosive vertical expansion clearing key resistance in a powerful V-recovery. Medical Supplies ($DJUSMS): $2042.70 (+2.27%), steady uptrend continuation clearing $2001.17 resistance. Pharmaceuticals ($DJUSPR): $1289.11 (+1.47%), bouncing strongly off $1217.54 support back into its broad range. $SPY

🟢 $XLV 195C Mar 19 💰 $111,000 premium 💵 $0/contract 📊 1.9x Vol/OI 📍 Spot $184.57 💰 Large premium | 🚨 Repeat sweep 🌊 Dark Flow | Options Flow

$XLV vs $XLC XLV is above its 20/50-day averages; XLC is below both. The weekly sector spread in a detailed charts view.

defense is winning … che k out $XLV and its components they get all the ai benefits and so maybe it could work beyond defense ?

$XLV $LLY $MRK Health care, week of Oct 26: 65 companies made news worth knowing. 📈 Good news led the week: nearly all the results from 26 health care companies, and most of the drug trial or approval news from 23, were good for shareholders 🚀 Eli Lilly, maker of Mounjaro and Zepbound, raised its 2026 sales outlook to $91–$92B from $85–$87B as third-quarter sales rose 39% to $24.4B ✂️ But Lilly cut its 2026 profit-per-share outlook to $35.00–$36.00 from $35.50–$36.50, as $4.57 a share in charges to buy unproven drug candidates outweighed a $4.07 underlying increase 📈 Merck's sac-TMT helped already-treated endometrial (uterus lining) cancer patients live a median 19.0 months versus 12.1 on chemotherapy; the FDA aims to decide by June 15, 2027 ⚠️ The bear case for Merck is that severe side effects hit 54.4% of sac-TMT patients versus 41.4% on chemotherapy, and these are interim (early) results

$XLV Health Care Sector ETF confirming its breakout with +5% push higher in morning trading. #IBDPartner

$XLV We did a deep dive on Health Care. 🏢 Health care was the busiest industry of the week, with 94 companies posting notable news versus 63 in industrials, the next busiest ✅ All 82 trial and approval filings and releases read as good for holders, led by Disc Medicine's final-stage trial win for a disorder that makes sunlight painful ⚠️ Disc then planned a $350M stock sale, about 11.5% of its value, despite saying in July its cash would last into 2029, so holders are diluted before the company needs the money 💰 Silence Therapeutics holders are offered $20.00 cash per US-traded share, a 130% premium to the $8.68 close the trading day before ⚠️ That cash is not locked in yet, because the Silence sale needs a 75% vote and only 14% has pledged so far 📅 Telix holders are expected to vote on the ITM merger on December 1, 2026, and Disc plans to reapply to the FDA by end-2026 Full report linked in the replies.

#sectorbreadth Two rank gain for Health Care ($XLV). Minor ranking changee elsewhere. Strongest sector is Utilities ($XLU) at 88% bulishness. Weakest is Technology ($XLK) at 45% bullishness.

With traders continuing to reach towards Health Care $XLV, Utilities $XLU, REITs $XLRE, and Consumer Staples $XLP, this market is adopting a distinct risk-off tone, hinting that market participants are preparing for a tougher period ahead.

$XLV Health Care Sector ETF attempting to break out. Bulls definitely need to see follow through if this is going to stick! #IBDPartner

$XLV found strong buyers in the 167.09 - 162.48 support area, triggering the expected rally. Long positions have already secured partial profits, while the remaining exposure is being held risk-free. Trade the Blue box. High frequency areas . #trading #Elliottwave

$XLV trade idea calling for a long entry in the extreme area at 167.09 - 162.48 was shared and discussed with members during the Live Trading Room session on 09.08.2026. Trade the Blue box. high frequency areas. #trading #Elliottwave

Meanwhile, State Street’s Health Care Select Sector ETF (XLV) gained 1.5$, reaching a 52-week high of $187. The fund’s top holdings including Eli Lilly , Johnson & Johnson , Pfizer , and Gilead all rising Friday with each stock reaching 52-week highs. Regeneron particularly stands out after the pharma company reported a strong third quarter print Friday morning that sent it stock soaring more than 12%. $XLV